

Set Name Query

side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=AND

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
<u>L10</u>	L3 and ((pseudorabies virus) or PRV)	9	<u>L10</u>
<u>L9</u>	L3 and ((particle adj mediated) or (gene adj gun) or (needleless adj injector))	37	<u>L9</u>
<u>L8</u>	L7 and (immune adj response)	98	<u>L8</u>
<u>L7</u>	L6 and (vector or plasmid)	202	<u>L7</u>
<u>L6</u>	L3 and (CMV or PRV)	202	<u>L6</u>
<u>L5</u>	L3 and ((coated or carrier) adj particle)	4	<u>L5</u>
<u>L4</u>	(enhancerless adj promoter)	8	<u>L4</u>
<u>L3</u>	(minimal adj promoter)	477	<u>L3</u>
<u>L2</u>	(minimal promoter)	12410	<u>L2</u>
<u>L1</u>	Fuller-james-t\$.in.	6	<u>L1</u>

END OF SEARCH HISTORY

Status: Path 1 of [Dialog Information Services via Modem]
Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
***** HHHHHHHH SSSSSSSS?
Status: Signing onto Dialog

ENTER PASSWORD:
***** HHHHHHHH SSSSSSSS? *****
Welcome to DIALOG
Status: Connected

Dialog level 02.03.27D

Last logoff: 03apr02 11:22:20
Logon file001 03apr02 15:52:58
KWIC is set to 50.
HIGHLIGHT set on as '*'
*

File 1:ERIC 1966-2002/Mar 02
(c) format only 2002 The Dialog Corporation

Set	Items	Description
Cost is in DialUnits		
?b 155, .5, 73		
03apr02 15:53:08 User259876 Session D331.1		
\$0.28 0.081 DialUnits File1		
\$0.28 Estimated cost File1		
\$0.03 TELNET		
\$0.31 Estimated cost this search		
\$0.31 Estimated total session cost	0.081	DialUnits

SYSTEM:OS = DIALOG OneSearch
File 155:MEDLINE(R) 1966-2002/Mar W5
File 5:Biosis Previews(R) 1969-2002/Mar W5
(c) 2002 BIOSIS
File 73:EMBASE 1974-2002/Mar W4
(c) 2002 Elsevier Science B.V.

*File 73: For information about Explode feature please
see Help News73.

Set	Items	Description
?s (minimal (w) promoter) or (enhancerless (w) promoter) or (truncated (w) promoter)		
268723	MINIMAL	
237115	PROMOTER	
2612	MINIMAL (W) PROMOTER	
273	ENHANCERLESS	
237115	PROMOTER	
23	ENHANCERLESS (W) PROMOTER	
181173	TRUNCATED	
237115	PROMOTER	
137	TRUNCATED (W) PROMOTER	
S1 2770	(MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (TRUNCATED (W) PROMOTER)	
?s s1 and (vector or plasmid)		
2770	S1	
183348	VECTOR	

163270 PLASMID
 S2 407 S1 AND (VECTOR OR PLASMID)
 ?s s2 and ((DNA or genetic) (w) (vaccination))
 407 S2
 1727634 DNA
 1104669 GENETIC
 119028 VACCINATION
 1738 (DNA OR GENETIC) (W) VACCINATION
 S3 0 S2 AND ((DNA OR GENETIC) (W) (VACCINATION))

?
 ?s s2 and (immune (w) response)
 407 S2
 1081478 IMMUNE
 2426746 RESPONSE
 178987 IMMUNE(W) RESPONSE
 S4 1 S2 AND (IMMUNE (W) RESPONSE)

?t s4/3,k/all

4/3,K/1 (Item 1 from file: 73)
 DIALOG(R) File 73:EMBASE
 (c) 2002 Elsevier Science B.V. All rts. reserv.

05203516 EMBASE No: 1992343750

A novel downstream regulatory element of the mouse H-2K^{sup b} class I major histocompatibility gene

Kralova J.; Jansa P.; Forejt J.
 Institute of Molecular Genetics, Czechoslovak Academy of Sciences,
 Videnska 1083, 142 20 Prague 4 Czechoslovakia
 EMBO Journal (EMBO J.) (United Kingdom) 1992, 11/12 (4591-4600)
 CODEN: EMJOD ISSN: 0261-4189

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

BH506 EC

The H-2K^{sup b} gene equipped with a *minimal* *promoter* (5' deletion up to -61) was fully expressed in transfected fibroblasts, but inactive in transfected embryonal carcinoma cells. A strong transcriptional, regulatory element (H2DRE) was...

MEDICAL DESCRIPTORS:

*dna responsive element; **immune* *response* gene; *transcription regulation

...enhancer region; exon; fibroblast; gene activation; gene activity; gene expression; genetic transfection; h2 system; intron; mouse; nonhuman; priority journal; promoter region; protein dna interaction; recombinant

plasmid; reporter gene; teratocarcinoma

?ds.

Set	Items	Description
S1	2770	(MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (-TRUNCATED (W) PROMOTER)
S2	407	S1 AND (VECTOR OR PLASMID)
S3	0	S2 AND ((DNA OR GENETIC) (W) (VACCINATION))
S4	1	S2 AND (IMMUNE (W) RESPONSE)
?s s2 and (antigen)		
	407	S2
	906577	ANTIGEN
S5	17	S2 AND (ANTIGEN)

?ds

Set	Items	Description
S1	2770	(MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (-TRUNCATED (W) PROMOTER)
S2	407	S1 AND (VECTOR OR PLASMID)
S3	0	S2 AND ((DNA OR GENETIC) (W) (VACCINATION))
S4	1	S2 AND (IMMUNE (W) RESPONSE)
S5	17	S2 AND (ANTIGEN)

?t s5/3,k/all

5/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

12906135 21848153 PMID: 11859419

Tumor-specific transcriptional targeting of suicide gene therapy.

Qiao J; Doubrovin M; Sauter B V; Huang Y; Guo Z S; Balatoni J; Akhurst T;
Blasberg R G; Tjuvajev J G; Chen S-H; Woo S L C

Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of
Medicine, New York, NY 10029, USA

Gene therapy (England) Feb 2002, 9 (3) p168-75, ISSN 0969-7128

Journal Code: 9421525

Contract/Grant No.: R01 CA-75175, CA, NCI; R01 CA69769, CA, NCI; R01
CA76177, CA, NCI; R024 CA98023, CA, NCI; R1 CA84404, CA, NCI; R29 CA-70337,
CA, NCI

Languages: ENGLISH

Document type: Journal Article

Record type: In Process

...to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic *antigen*) driving a transcription transactivator, which then activates a *minimal* *promoter* to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner *in vitro* compared with the CEA-independent killing of a *vector* with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression *in vivo*, we employed noninvasive nuclear...

... intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy *vector* is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

5/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

09673155 98158534 PMID: 9498769

PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter.

Ying H; Chang JF; Parnes JR

Department of Medicine, Stanford University School of Medicine, CA 94305,
USA.

Journal of immunology (UNITED STATES) Mar 1 1998, 160 (5) p2287-96,
ISSN 0022-1767 Journal Code: IFB

Contract/Grant No.: CA09302, CA, NCI; CA68675, CA, NCI

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

... The CD72 gene does not have an obvious TATAA box. Primer extension assays identified multiple transcription initiation sites. Deletion analyses have identified the 255-bp *minimal* *promoter* required for tissue-specific and developmental stage-specific expression. DNase I footprinting analysis of the CD72 *minimal* *promoter* revealed three protected elements: FP I, FP II, and FP III. Sequences corresponding to FP I or III gave increased reporter gene activity specifically in...

... shift assays and DNase I protection analyses revealed that FP I was bound by the transcription factor PU.1/Spi-1. Transient reporter analyses with *plasmid* bearing the mutated PU.1 binding site showed that binding of PU.1 is necessary for the increase in CD72 promoter activity in B cells...

Chemical Name: Antigens, CD; Antigens, Differentiation, B-Lymphocyte;
CD72 *antigen*; Nuclear Proteins; Proto-Oncogene Proteins; Trans-Activators

; proto-oncogene protein Spi-1

5/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

08328340 95128183 PMID: 7827504

Purification of recombinant human transcription factor IIB by immunoaffinity chromatography.

Thompson NE; Burgess RR

McArdle Laboratory for Cancer Research, University of Wisconsin at Madison 53706.

Protein expression and purification (UNITED STATES) Oct 1994, 5 (5) p468-75, ISSN 1046-5928 Journal Code: BJV

Contract/Grant No.: CA07175, CA, NCI; CA23076, CA, NCI; GM28575, GM, NIGMS

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

... Mouse monoclonal antibodies (MAbs) were prepared that react with TFIIB. A modified enzyme-linked immunosorbent assay was used to screen for MAbs that release the *antigen* in the presence of a low molecular weight polyhydroxylated compound and a nonchaotropic salt (polyol-responsive MAbs). One polyol-responsive MAb (designated IIB8) was purified by chromatography on protein A and conjugated to cyanogen bromide-activated Sepharose 4B. Escherichia coli strain BL21 (DE3) containing the pLySS *plasmid* was transformed with the human TFIIB gene contained in the pET11a *vector*. After induction with IPTG, the cells were harvested and lysed. The lysate was treated with 0.5% polyethyleneimine and centrifuged. The supernatant fluid was...

... sulfate and 40% propylene glycol. The purified TFIIB was active when added back to TFIIB-depleted HeLa nuclear extract and when used in the IgH *minimal* *promoter* system. This method will be useful for the rapid purification of TFIIB mutants and for the purification of large amounts of highly purified TFIIB for...

5/3,K/4 (Item 4 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

07808058 92408011 PMID: 1356162

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.

Deb S; Jackson CT; Subler MA; Martin DW

Department of Microbiology, University of Texas Health Science Center, San Antonio 78284-7758.

Journal of virology (UNITED STATES) Oct 1992, 66 (10) p6164-70, ISSN 0022-538X Journal Code: KCV

Contract/Grant No.: AI07271-08, AI, NIAID

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

... mutations of p53 on promoter functions. We, therefore, have studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear *antigen* (PCNA) promoter and on several viral promoters, including the herpes simplex virus type 1 UL9 promoter, the human cytomegalovirus major immediate-early promoter-enhancer, and...

...promoters of Rous sarcoma virus and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression *vector* and a *plasmid* containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. As expected, expression of the wild-type p53 inhibited promoter function. Expression of

... 11-fold). The viral promoters were also activated, although to a somewhat lesser extent. We also showed that activation by a mutant p53 requires a *minimal* *promoter* containing a lone TATA box. A more significant increase (25-fold) in activation occurs when the promoter contains a binding site for the activating transcription...

...; Cyclic AMP-Responsive; DNA-Binding Proteins--metabolism--ME; HTLV-I --genetics--GE; Hela Cells; Molecular Sequence Data; Nuclear Proteins --genetics--GE; Plasmids; Proliferating Cell Nuclear *Antigen*; Protein p53 --genetics--GE; Sarcoma Viruses; Avian--genetics--GE; Simplexvirus --genetics--GE; Trans-Activation (Genetics); Transcription Factors --metabolism--ME; Transfection

Chemical Name: Blood Proteins; DNA-Binding Protein, Cyclic AMP-Responsive ; DNA-Binding Proteins; Nuclear Proteins; Plasmids; Proliferating Cell Nuclear *Antigen*; Protein p53; Transcription Factors; common cellular transcription factor ATF; Chloramphenicol O-Acetyltransferase

5/3,K/5 (Item 5 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

07135376 93200516 PMID: 8384027

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes.

Burns LJ; Waring JF; Reuter JJ; Stinski MF; Ginder GB
Department of Medicine, University of Minnesota, Minneapolis.
Blood (UNITED STATES) Mar 15 1993, 81 (6) p1558-66, ISSN 0006-4971

Journal Code: A8G

Contract/Grant No.: AI13562, AI, NIAID, CA45634, CA, NCI

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

RBIUS.A2 BSC

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes.

... investigated. Transient expression assays were performed using plasmids containing the HLA A2 promoter-regulatory region linked to the bacterial chloramphenicol acetyltransferase (CAT) gene and a *plasmid* expressing the CMV IE genes. The upregulation of the HLA A2 promoter by HCMV IE gene products was shown not to be secondary to either...

Descriptors: Cytomegalovirus--genetics--GE; *Genes, MHC Class I; *Genes, Viral; *HLA-A2 *Antigen--genetics--GE; *Promoter Regions (Genetics); *Trans-Activation (Genetics)

Chemical Name: HLA-A2 *Antigen*; Interferon-alpha; Interferon Type II; Chloramphenicol O-Acetyltransferase

5/3,K/6 (Item 1 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13570660 BIOSIS NO.: 200200199481

Tumor-specific transcriptional targeting of suicide gene therapy.

AUTHOR: Qiao J; Doubrovin M; Sauter B V; Huang Y; Guo Z S; Balatoni J; Akhurst T; Blasberg R G; Tjuvajev J G; Chen S-H; Woo S L C(a)

AUTHOR ADDRESS: (a) Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY, 10029**USA

JOURNAL: Gene Therapy 9 (3):p168-175 February, 2002

MEDIUM: print

ISSN: 0969-7128

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: to increase promoter strength while maintaining tissue

specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic *antigen*) driving a transcription transactivator, which then activates a *minimal* *promoter* to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner *in vitro* compared with the CEA-independent killing of a *vector* with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression *in vivo*, we employed noninvasive nuclear...

...intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy *vector* is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

DESCRIPTORS:

...ORGANISMS: ADV/RSV-tk, gene *vector*; ...

...ADV/binary-tk, gene *vector*, recombinant

CHEMICALS & BIOCHEMICALS: ...carcinoembryonic *antigen* (CEA...)

MISCELLANEOUS TERMS: ...intravenous gene *vector* administration...

5/3,K/7 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

12979893 BIOSIS NO.: 200100187042

Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.

AUTHOR: Xie Xiaoming; Zhao Xiuqin; Liu Yuanfang; Young Charles Y F; Tindall Donald J; Slawin Kevin M; Spencer David M(a)

AUTHOR ADDRESS: (a) Department of Immunology, Baylor College of Medicine, One Baylor Plaza/M929, Houston, TX, 77030-3498: dspencer@bcm.tmc.edu**USA

JOURNAL: Human Gene Therapy 12 (5):p549-561 March 20, 2001

MEDIUM: print

ISSN: 1043-0342

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Tissue-specific transcriptional regulatory elements can increase the safety of gene therapy vectors. Unlike prostate-specific *antigen* (PSA/hK3), whose expression displays an inverse correlation with prostate cancer grade and stage, human glandular kallikrein 2 (hK2) is upregulated in higher grade and...

...minimum "full-strength" hK2 enhancer and built transcriptional regulatory elements composed of multiple tandem copies of this 1.2-kb enhancer, fused to the hK2 *minimal* *promoter*. Relative to the weak induction of the minimal hK2 promoter by androgen analog (R1881) in androgen receptor (AR)-positive LNCaP cells, transcriptional activity was increased...

DESCRIPTORS:

...ORGANISMS: gene *vector*

5/3,K/8 (Item 3 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

09505969 BIOSIS NO.: 199497514339

Purification of recombinant human transcription factor IIB by immunoaffinity chromatography.

AUTHOR: Thompson Nancy E; Burgess Richard R

AUTHOR ADDRESS: McArdle Lab. Cancer Res., Univ. Wisconsin Madison,

Madison, WI 53706**USA

JOURNAL: Protein Expression and Purification 5 (5):p468-475 1994

ISSN: 1046-5928

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: Mouse monoclonal antibodies (MAbs) were prepared that react with TFIIB. A modified enzyme-linked immunosorbent assay was used to screen for MAbs that release the *antigen* in the presence of a low molecular weight polyhydroxylated compound and a nonchaotropic salt (polyol-responsive MAbs). One polyol-responsive MAb (designated IIB8) was purified by chromatography on protein A and conjugated to cyanogen bromide-activated Sepharose 4B. Escherichia coli strain BL21(DE3) containing the pLyss *plasmid* was transformed with the human TFIIB gene contained in the pET11 a *vector* (phiIIB). After induction with IPTG, the cells were harvested and lysed. The lysate was treated with 0.5% polyethyleneimine and centrifuged. The supernatant fluid was...

...sulfate and 40% propylene glycol. The purified TFIIB was active when added back to TFIIB-depleted HeLa nuclear extract and when used in the IgH *minimal* *promoter* system. This method will be useful for the rapid purification of TFIIB mutants and for the purification of large amounts of highly purified TFIIB for...

5/3,K/9 (Item 4 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

08426188 BIOSIS NO.: 000094133392

**MODULATION OF CELLULAR AND VIRAL PROMOTERS BY MUTANT HUMAN P53 PROTEINS
FOUND IN TUMOR CELLS**

AUTHOR: DEB S; JACKSON C T; SUBLER M A; MARTIN D W

AUTHOR ADDRESS: DEP. MICROBIOLOGY, UNIVERSITY TEXAS HEALTH SCIENCE CENTER,
SAN ANTONIO, TEX. 78284-7758.

JOURNAL: J VIROL 66 (10). 1992. 6164-6170. 1992

FULL JOURNAL NAME: Journal of Virology

CODEN: JOVIA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

QR 355/J65

...ABSTRACT: mutations of p53 on promoter functions. We, therefore, have studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear *antigen* (PCNA) promoter and on several viral promoters, including the herpes simplex virus type 1 UL9 promoter, the human cytomegalovirus major immediate-early promoter-enhancer, and...

...promoters of Rous sarcoma virus and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression *vector* and a *plasmid* containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. As expected, expression of the wild-type p53 inhibited promoter function. Expression of...

...11-fold). The viral promoters were also activated, although to a somewhat lesser extent. We also showed that activation by a mutant p53 required a *minimal* *promoter* containing a lone TATA box. A more significant increase (25-fold) in activation occurs when the promoter contains a binding site for the activating transcription...

...DESCRIPTORS: HUMAN CYTOMEGALOVIRUS MAJOR IMMEDIATE-EARLY

PROMOTER-ENHANCER ROUS SARCOMA VIRUS LONG TERMINAL REPEAT HUMAN T LYMPHOTROPIC VIRUS TYPE I LONG TERMINAL REPEAT PROLIFERATING CELL NUCLEAR *ANTIGEN* GENE GENE REGULATION TRANSCRIPTION REPRESSION TRANSCRIPTION ACTIVATION CELL PROLIFERATION CONTROL TUMOR SUPPRESSOR GENE PRODUCT

5/3,K/10 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

11514883 EMBASE No: 2002086429

Tumor-specific transcriptional targeting of suicide gene therapy

Qiao J.; Doubrovin M.; Sauter B.V.; Huang Y.; Guo Z.S.; Balatoni J.; Akhurst T.; Blasberg R.G.; Tjuvajev J.G.; Chen S.-H.; Woo S.L.C.

S.L.C. Woo, Mount Sinai School of Medicine, Inst. Gene Therapy/Mol. Medicine, 1425 Madison Avenue, New York, NY 10029 United States

Gene Therapy (GENE THER.) (United Kingdom) 2002, 9/3 (168-175)

CODEN: GETHE ISSN: 0969-7128

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 39

...to increase promoter strength while maintaining tissue specificity, we constructed a recombinant adenovirus containing a binary promoter system with a tumor-specific promoter (CEA; carcinoembryonic *antigen*) driving a transcription transactivator, which then activates a *minimal* *promoter* to express a suicide gene (HSV-tk; herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a *vector* with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear...

...intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEA-driven suicide gene therapy *vector* is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.

DRUG DESCRIPTORS:

carcinoembryonic *antigen*--drug dose--do; carcinoembryonic *antigen*--drug therapy--dt; carcinoembryonic *antigen*--drug toxicity--to; carcinoembryonic *antigen*--pharmacology--pd; carcinoembryonic *antigen* --intravenous drug administration--iv; transactivator protein; thymidine kinase--intratumoral drug administration--tu; thymidine kinase--intravenous drug administration--iv; nucleoside analog; uracil derivative

MEDICAL DESCRIPTORS:

gene expression; tissue specificity; promoter region; virus recombinant; adenovirus *vector*; Herpes simplex virus; cell killing; in vitro study; in vivo study; imaging; enzyme substrate; radioactivity; Respiratory syncytial pneumovirus; drug efficacy; liver metastasis--drug therapy--dt...

5/3,K/11 (Item 2 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

11185960 EMBASE No: 2001201564

Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter

Xie X.; Zhao X.; Liu Y.; Young C.Y.F.; Tindall D.J.; Slawin K.M.; Spencer D.M.

Dr. D.M. Spencer, Department of Immunology, Baylor College of Medicine, One Baylor Plaza/M929, Houston, TX 77030-3498 United States

AUTHOR EMAIL: dspencer@bcm.tmc.edu

Human Gene Therapy (HUM. GENE THER.) (United States) 23 MAR 2001,

12/5 (549-561)

CODEN: HGTHE ISSN: 1043-0342

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 39

Tissue-specific transcriptional regulatory elements can increase the safety of gene therapy vectors. Unlike prostate-specific *antigen* (PSA/hK3), whose expression displays an inverse correlation with prostate cancer grade and stage, human glandular kallikrein 2 (hK2) is upregulated in higher grade and...

...minimum "full-strength" hK2 enhancer and built transcriptional regulatory elements composed of multiple tandem copies of this 1.2-kb enhancer, fused to the hK2 *minimal* *promoter*. Relative to the weak induction of the minimal hK2 promoter by androgen analog (R1881) in androgen receptor (AR)-positive LNCaP cells, transcriptional activity was increased...

MEDICAL DESCRIPTORS:

tissue specificity; gene induction; transcription regulation; virus recombinant; Adenovirus; RNA analysis; reverse transcription polymerase chain reaction; virus *vector*; human; nonhuman; mouse; animal experiment; animal model; human cell; article; nucleotide sequence

5/3,K/12 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

10983307 EMBASE No: 2001025519

A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo

Zhang J.; Thomas T.Z.; Kasper S.; Matusik R.J.
Dr. R.J. Matusik, Department of Urologic Surgery, A-1302 Medical Center North, Vanderbilt University Medical Center, Nashville, TN 37232-2765 United States

AUTHOR EMAIL: robert.matusik@mcmail.vanderbilt.edu

Endocrinology (ENDOCRINOLOGY) (United States) 2000, 141/12
(4698-4710)

CODEN: ENDOA ISSN: 0013-7227

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 42

...by androgens and, in addition, glucocorticoids. This demonstrates that the necessary sequences required to target prostate-specific epithelial expression are contained within the composite ARRSUB2PB *minimal* *promoter*, and that high transgene expression can now be regulated by both androgens and glucocorticoids. The ARRSUB2PB promoter represents a novel glucocorticoid inducible promoter that can...

DRUG DESCRIPTORS:

*probasin; *prostate specific *antigen*; *androgen; *glucocorticoid

MEDICAL DESCRIPTORS:

genetic transfection; transgenic mouse; regulatory mechanism; transgene; gene expression; gene induction; cell strain COS1; cell line; enzyme activity; castration; prostate epithelium; gene therapy; DNA *vector*; prostate cancer; human; nonhuman; mouse; animal experiment; animal model; controlled study; human cell; animal tissue; animal cell; article; priority journal

5/3,K/13 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

07207354 EMBASE No: 1998085712

PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter

Ying H.; Chang J.-F.; Parnes J.R.

Dr. J.R. Parnes, Div. of Immunology and Rheumatology, MSLS, Stanford University Medical Center, Stanford, CA 94305-5487 United States
Journal of Immunology (J. IMMUNOL.) (United States) 01 MAR 1998, 160/5

(2287-2296)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 63

...The CD72 gene does not have an obvious TATAA box. Primer extension assays identified multiple transcription initiation sites. Deletion analyses have identified the 255-bp *minimal* *promoter* required for tissue-specific and developmental stage-specific expression. DNase I footprinting analysis of the CD72 *minimal* *promoter* revealed three protected elements: FP I, FP II, and FP III. Sequences corresponding to FP I or III gave increased reporter gene activity specifically in...

...shift assays and DNase I protection analyses revealed that FP I was bound by the transcription factor PU.1/Spi-1. Transient reporter analyses with *plasmid* bearing the mutated PU.1 binding site showed that binding of PU.1 is necessary for the increase in CD72 promoter activity in B cells...

DRUG DESCRIPTORS:

*cd72 *antigen*

5/3,K/14 (Item 5 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

05701696 EMBASE No: 1994108105

The human beta2 integrin CD18 promoter consists of two inverted Ets cis elements

Bottlinger E.P.; Shelley C.S.; Farokhzad O.C.; Arnaout M.A.

Leukocyte Biology/Inflammation Prog., Massachusetts General Hospital, 149
13th St., Charlestown, MA 02129 United States

Molecular and Cellular Biology (MOL. CELL. BIOL.) (United States) 1994
14(4) (2604-2615)

CODEN: MCEBBD ISSN: 0270-7306

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

QH506.MG

To define the *minimal* *promoter* responsible for expression of CD18 in myeloid and lymphoid cells, we generated 5' and 3' deletion constructs of a segment extending 785 bp upstream and...

...a construct of 47 nt in length containing box A and box B and lacking other 3' or 5' elements was cloned into a promoterless *vector*, it conferred tissue-specific and phorbol ester-inducible expression. Gel retardation revealed that the protein components of two major protein-DNA complexes that form on...

DRUG DESCRIPTORS:

*cd18 *antigen*; *integrin

MEDICAL DESCRIPTORS:

**antigen* expression; *dna flanking region; *promoter region; *genetic transfection

5/3,K/15 (Item 6 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

05315750 EMBASE No: 1993083835

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes

Burns L.J.; Waring J.F.; Reuter J.J.; Stinski M.F.; Ginder G.D.

Division of Medical Oncology, Department of Medicine, Minnesota University Hospital/Clinic, Minneapolis, MN 55455 United States

Blood (BLOOD) (United States) 1993, 81/6 (1558-1566)

CODEN: BLOOA ISSN: 0006-4971

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes

...investigated. Transient expression assays were performed using plasmids containing the HLA A2 promoter-regulatory region linked to the bacterial chloramphenicol acetyltransferase (CAT) gene and a *plasmid* expressing the CMV IE genes. The upregulation of the HLA A2 promoter by HCVM IE gene products was shown not to be secondary to either...

DRUG DESCRIPTORS:

*HLA A2 *antigen*--endogenous compound--ec; *HLA *antigen* class 1 --endogenous compound--ec
alpha interferon; chloramphenicol acetyltransferase; gamma interferon; gene product; major histocompatibility *antigen* class 1

5/3,K/16 (Item 7 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

05203516 EMBASE No: 1992343750

A novel downstream regulatory element of the mouse H-2K^{sup b} class I major histocompatibility gene

Kralova J.; Jansa P.; Forejt J.

Institute of Molecular Genetics, Czechoslovak Academy of Sciences,
Videnska 1083,142 20 Prague 4 Czechoslovakia

EMBO Journal (EMBO J.) (United Kingdom) 1992, 11/12 (4591-4600)

CODEN: EMJOD ISSN: 0261-4189

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The H-2K^{sup b} gene equipped with a *minimal* *promoter* (5' deletion up to -61) was fully expressed in transfected fibroblasts, but inactive in transfected embryonal carcinoma cells. A strong transcriptional, regulatory element (H2DRE) was...

DRUG DESCRIPTORS:

*major histocompatibility *antigen* class 1--endogenous compound--ec

MEDICAL DESCRIPTORS:

...enhancer region; exon; fibroblast; gene activation; gene activity; gene expression; genetic transfection; h2 system; intron; mouse; nonhuman; priority journal; promoter region; protein dna interaction; recombinant *plasmid*; reporter gene; teratocarcinoma

5/3,K/17 (Item 8 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

05157660 EMBASE No: 1992297893

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

Deb S.; Jackson C.T.; Subler M.A.; Martin D.W.

Department of Microbiology, Univ. of Texas Health Science Center, San Antonio, TX 78284-7758 United States

Journal of Virology (J. VIROL.) (United States) 1992, 66/10 (6164-6170)

CODEN: JOVIA ISSN: 0022-538X

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...mutations of p53 on promoter functions. We, therefore, have studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear *antigen* (PCNA) promoter and on several viral promoters, including the herpes simplex virus type 1 UL9 promoter, the human cytomegalovirus major immediate-early promoter-enhancer, and...

...promoters of Rous sarcoma virus and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression *vector* and a *plasmid* containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. As expected, expression of the wild-type p53 inhibited promoter function. Expression of

...11-fold). The viral promoters were also activated, although to a somewhat lesser extent. We also showed that activation by a mutant p53 requires a *minimal* *promoter* containing a lone TATA box. A more significant increase (25-fold) in activation occurs when the promoter contains a binding site for the activating transcription...
?ds

Set Items Description
S1 2770 (MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (- TRUNCATED (W) PROMOTER)
S2 407 S1 AND (VECTOR OR PLASMID)
S3 0 S2 AND ((DNA OR GENETIC) (W) (VACCINATION))
S4 1 S2 AND (IMMUNE (W) RESPONSE)
S5 17 S2 AND (ANTIGEN)
?s s2 and (coated (w) particles)
 407 S2
 100981 COATED
 201164 PARTICLES
 961 COATED(W)PARTICLES
S6 0 S2 AND (COATED (W) PARTICLES)
?s s2 and ((particle (w) mediated) or (gene (w) gun) or (needleless (w) injector))
 407 S2
 126460 PARTICLE
 850115 MEDIATED
 438 PARTICLE(W)MEDIATED
1798880 GENE
 6890 GUN
 918 GENE(W)GUN
 442 NEEDLELESS
 3896 INJECTOR
 52 NEEDLELESS(W)INJECTOR
S7 0 S2 AND ((PARTICLE (W) MEDIATED) OR (GENE (W) GUN) OR (NEEDLELESS (W) INJECTOR))
?s s2 and (CMV or PRV)
 407 S2
 28595 CMV
 2727 PRV
S8 20 S2 AND (CMV OR PRV)
?rd
...completed examining records
S9 9 RD (unique items)
?t s9/3,k/all

9/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

12984011 21877094 PMID: 11882625

Vigilant *vector*: heart-specific promoter in an adeno-associated virus *vector* for cardioprotection.

Phillips M Ian; Tang Yi; Schmidt-Ott Kai; Qian Keping; Kagiyama Shuntaro
Department of Physiology and Functional Genomics, University of Florida,
Gainesville, FL 32610-0274, USA. MIP@ufl.edu

Hypertension (United States) Feb 2002, 39 (2 Pt 2) p651-5, ISSN
1524-4563 Journal Code: 7906255

Contract/Grant No.: HL 27339, HL, NHLBI

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Vigilant *vector*: heart-specific promoter in an adeno-associated virus *vector* for cardioprotection.

... term protection of the heart from ischemia, there is no known mechanism for constantly responding to repeated incidences of ischemia. We hypothesized that a "vigilant *vector*", designed to be expressed specifically in the heart and switch on therapeutic genes only during hypoxia, would provide cardioprotection. To attain cardiac specificity, we inserted...

... gfp. In in-vitro experiments in cardiomyocytes (H9C2 cells), the MLC2v-AAV-gfp drove gene expression in all cells at levels comparable to a cytomegalovirus (*CMV*) promoter. In in vivo experiments, the rAAV-MLC2v-gfp was injected intravenously into mice or rats. Green fluorescence protein (GFP) DNA was located in kidney...

...ischemia, we inserted a hypoxia response element (HRE). This upregulates transcription when O₂ levels are low. Thus, there are 4 components to the vigilant *vector*; a gene switch (HRE), a heart-specific promoter (MLC2v), a therapeutic gene (AS-AT(1)R) and a reporter gene (gfp). To silence or lower...

... level of expression while retaining specificity, we have reduced the length of the MLC2v promoter from 3 kb to 1775 bp or 281 bp. The *truncated* *promoter* is equally effective in heart specific expression. Preliminary studies with the rAAV-HRE-gfp in vitro show an increased expression in 1% O₂ in...

... by 4-fold in 1% O₂. Further amplification of the gene to 400-fold in 1% O₂ can be achieved with a double *plasmid*. The construct may serve as a prototype "vigilant *vector*" to switch on therapeutic genes in specific tissue with physiological signals.

9/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

10956593 20498131 PMID: 11045432

HSV-1 infected cell proteins influence tetracycline-regulated transgene expression.

Herrlinger U; Pechan PA; Jacobs AH; Woiciechowski C; Rainov NG; Fraefel C ; Paulus W; Reeves SA

Neurology Service, Massachusetts General Hospital and Harvard Medical School, Charlestown 02129, USA. ~~ulrich.herrlinger@uni-tuebingen.de~~

Journal of gene medicine (ENGLAND) Sep-Oct 2000, 2 (5) p379-89,
ISSN 1099-498X Journal Code: DLU

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

... with helper virus-free amplicon vectors. Elevation of luciferase expression was also observed upon infection with the same HSV-1 mutants following transfection with a *plasmid* containing only a *CMV* *minimal* *promoter* driving luciferase (pUHC13-3). Only one HSV mutant (14Hdelta3), which bears a disruption in the transactivation domain of VP16 and is deleted for both ICP4...

... dose and were not influenced by treatment with interferon (IFN)-alpha, which suppresses viral gene expression. Additional assays involving cotransfection of pUHC13-3 with a *plasmid* encoding of the HSV-1 transactivating factor ICP4 revealed that ICP4 was the most potent inducer of gene expression from the tetO/*CMV* *minimal* *promoter*. CONCLUSION: These results indicate that proteins encoded in the HSV-1 genome, especially the transactivating immediate early gene products (ICP4, ICP27 and ICP0) and the VP16 tegument protein can activate the tetO/ minimal *CMV* promoter and thereby interfere with the integrity of tetracycline-regulated transgene expression.

9/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

10765499 20411448 PMID: 10954575

Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.

Haberman RP; McCown TJ; Samulski RJ

UNC Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA.

Journal of virology (UNITED STATES) Sep 2000, 74 (18) p8732-9,

ISSN 0022-538X Journal Code: KCV

Contract/Grant No.: DK51880, DK, NIDDK; NS35633, NS, NINDS

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

...rat brains. In that study, we also observed residual expression in the "off" state both in vitro and in vivo, suggesting that the human cytomegalovirus (*CMV*) major immediate-early *minimal* *promoter* or other cis-acting elements (AAV terminal repeats [TR]) were contributing to this activity. In the present study, we identify that the AAV TR, minus the tetracycline-responsive minimal *CMV* promoter, will initiate mRNA expression from *vector* templates. Using deletion analysis and specific PCR-derived TR reporter gene templates, we mapped this activity to a 37-nucleotide stretch in the A/D.. .

9/3,K/4 (Item 4 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

10555145 20220521 PMID: 10757022

Development of a hypoxia-responsive *vector* for tumor-specific gene therapy.

Shibata T; Giaccia AJ; Brown JM

Mayer Cancer Biology Research Laboratory, Department of Radiation Oncology, Stanford University School of Medicine, CA 94305-5468, USA.

Gene therapy (ENGLAND) Mar 2000, 7 (6) p493-8, ISSN 0969-7128

Journal Code: CCE

Contract/Grant No.: P01 CA-67166, CA, NCI

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Development of a hypoxia-responsive *vector* for tumor-specific gene therapy.

... we found no benefit from the inclusion of the 3' UTR in our vectors. Of all the vectors tested, the combination of 5HRE and a *CMV* *minimal* *promoter* exhibited hypoxia responsiveness (over 500-fold) to the similar level to the intact *CMV* promoter. We propose that this *vector* would be useful for tumor selective gene therapy.

9/3,K/5 (Item 5 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

09947576 99059254 PMID: 9845121

Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes.

Shibata T; Akiyama N; Noda M; Sasai K; Hiraoka M

Department of Radiology, Faculty of Medicine, Kyoto University, Japan.

International journal of radiation oncology, biology, physics (UNITED STATES) Nov 1 1998, 42 (4) p913-6, ISSN 0360-3016 Journal Code: G97

Languages: ENGLISH

Document type: Journal Article
Record type: Completed

... fragments of the human vascular endothelial growth factor (VEGF) and the erythropoietin (Epo) genes encompassing the putative hypoxia-responsive elements (HRE) and the pGL3 promoter *vector*. Test plasmids and the control pRL-*CMV* *plasmid* were cotransfected into tumor cells by the calcium phosphate method. After 6 h hypoxic treatment, the reporter assay was performed. RESULTS: The construct pGL3/VEGF...

... in human cell lines. The insertion of 5 copies of the 35-bp fragments derived from the VEGF HREs and 32 bp of the Elb *minimal* *promoter* resulted in maximal enhancement of hypoxia responsiveness. CONCLUSIONS: The constructs with VEGF or Epo fragments containing HRE may be useful for inducing specific gene expression in hypoxic cells. Especially, the application of multiple copies of the HREs and an Elb *minimal* *promoter* appears to have the advantage of great improvement in hypoxia responsiveness.

9/3,K/6 (Item 6 from file: 155)
DIALOG(R) File 155: MEDLINE(R)

07135376 93200516 PMID: 8384027

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes.

Burns LJ; Waring JF; Reuter JJ; Stinski MF; Ginder GD

Department of Medicine, University of Minnesota, Minneapolis.

Blood (UNITED STATES) Mar 15 1993, 81 (6) p1558-66, ISSN 0006-4971.

Journal Code: A8G

Contract/Grant No.: AI13562, AI, NIAID; CA45634, CA, NCI

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Only the HLA class I gene *minimal* *promoter* elements are required for transactivation by human cytomegalovirus immediate early genes.

... investigated. Transient expression assays were performed using plasmids containing the HLA A2 promoter-regulatory region linked to the bacterial chloramphenicol acetyltransferase (CAT) gene and a *plasmid* expressing the *CMV* IE genes. The upregulation of the HLA A2 promoter by HCVM IE gene products was shown not to be secondary to either interferon-gamma or...

9/3,K/7 (Item 1 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13409673 BIOSIS NO.: 200200038494

Differential neuronal gene expression from two non-specific promoters after recombinant adeno-associated virus (rAAV) 2 transduction in vivo.

AUTHOR: Haberman R P(a); Zhou X(a); McCown T J(a)

AUTHOR ADDRESS: (a)Gene Therapy Center, University of North Carolina, Chapel Hill, NC**USA

JOURNAL: Society for Neuroscience Abstracts 27 (2):p2345 2001

MEDIUM: print

CONFERENCE/MEETING: 31st Annual Meeting of the Society for Neuroscience San Diego, California, USA November 10-15 2001

ISSN: 0190-5295

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: in the CNS, but not all neurons exhibit gene expression. Even when gene expression is driven by ubiquitous promoters, such as the cytomegalovirus immediate early (*CMV*) promoter or the chicken beta

actin promoter, a substantial number of neurons do not express the transgene. A number of processes determine viral entry, but...

...the tetracycline responsive promoter. The CAG promoter is a hybrid promoter composed of the basal promoter sequences from the chicken beta-actin gene and the *CMV* enhancer. The tetracycline responsive promoter combines a *CMV* *minimal* *promoter* with the tetracycline transactivator (tTAK) binding element. When 0.5 μl of the rAAV2-CAG-eGFP was infused into the cortex just dorsal to the...

DESCRIPTORS:

...MAJOR CONCEPTS: *Vector* Biology

...ORGANISMS: gene *vector*

9/3,K/8 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

12979893 BIOSIS NO.: 200100187042

Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.

AUTHOR: Xie Xiaoming; Zhao Xiuqin; Liu Yuanfang; Young Charles Y F; Tindall Donald J; Slawin Kevin M; Spencer David M(a)

AUTHOR ADDRESS: (a) Department of Immunology, Baylor College of Medicine, One Baylor Plaza/M929, Houston, TX, 77030-3498: dspencer@bcm.tmc.edu**USA

JOURNAL: Human Gene Therapy 12 (5):p549-561 March 20, 2001

MEDIUM: print

ISSN: 1043-0342

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

...ABSTRACT: minimum "full-strength" hK2 enhancer and built transcriptional regulatory elements composed of multiple tandem copies of this 1.2-kb enhancer, fused to the hK2 *minimal* *promoter*. Relative to the weak induction of the minimal hK2 promoter by androgen analog (R1881) in androgen receptor (AR)-positive LNCaP cells, transcriptional activity was increased...

...hK2-E3/P-EGFP, expressing enhanced green fluorescent protein (EGFP) under the control of the hK2 triplicate enhancer/promoter, and compared its properties with ADV.*CMV*-EGFP expressing EGFP under the control of the cytomegalovirus (*CMV*) enhancer/promoter. Unlike the *CMV* promoter, the hK2-E3/P promoter was at least 100-fold inducible by R1881 in the adenoviral backbone. Compared with in situ injection of subcutaneous LNCaP tumors with ADV.*CMV*-EGFP, which led to detectable EGFP expression in tumor, liver, and brain tissue, ADV.hK2-E3/P-EGFP injection led to robust but tumor-restricted...

DESCRIPTORS:

...ORGANISMS: gene *vector*

9/3,K/9 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

04956455 EMBASE No: 1992096671

Cell adhesion molecules as targets for Hox genes: Neural cell adhesion molecule promoter activity is modulated by cotransfection with Hox-2.5 and -2.4

Jones F.S.; Prediger E.A.; Bittner D.A.; De Robertis E.M.; Edelman G.M. Laboratory of Developmental and Molecular Biology, Rockefeller University, 1230 York Avenue, New York, NY 10021 United States Proceedings of the National Academy of Sciences of the United States of America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 1992, 89/6 (2086-2090)

CODEN: PNASA ISSN: 0027-8424
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...experiments using NIH 3T3 cells. Plasmids were constructed containing Xenopus laevis Hox-2.5 and -2.4 coding sequences linked to a human cytomegalovirus promoter (*CMV*-Hox-2.5 and *CMV*- Hox-2.4). A 4.9-kilobase DNA fragment containing 5' flanking and first exon sequences of the mouse N-CAM gene was linked to a chloramphenicol acetyltransferase (CAT) reporter gene (N-CAM-Pro-CAT). Cotransfection with *CMV*-Hox-2.5 and N-CAM-Pro-CAT resulted in a strong induction of CAT activity. The N-CAM promoter contained two potential homeodomain binding...

...segment (512-559 base pairs upstream of the ATG codon in the first exon of the N-CAM gene). This segment was linked to a *minimal* *promoter* (simian virus 40 early) and a downstream CAT gene. Although this construct was transcriptionally active at a low level in NIH 3T3 cells, cotransfection of *CMV*-Hox-2.5 resulted in CAT activity that was greatly elevated. Mutational studies revealed that it was the homeodomain binding site II sequence that was required for this regulation. In contrast, cotransfection with *CMV*-Hox-2.4 eliminated the CAT activity that was driven by the *CMV*-Hox-2.5 construct. Thus, the products of two related Hox genes, which are located adjacent to each other in the Hox-2 complex, can...

MEDICAL DESCRIPTORS:

article; binding site; cell interaction; cell strain 3t3; cytomegalovirus; enzyme activity; gene expression; nonhuman; *plasmid*; priority journal; reporter gene; xenopus laevis

?ds

Set	Items	Description
S1	2770	(MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (- TRUNCATED (W) PROMOTER)
S2	407	S1 AND (VECTOR OR PLASMID)
S3	0	S2 AND ((DNA OR GENETIC) (W) (VACCINATION))
S4	1	S2 AND (IMMUNE (W) RESPONSE)
S5	17	S2 AND (ANTIGEN)
S6	0	S2 AND (COATED (W) PARTICLES)
S7	0	S2 AND ((PARTICLE (W) MEDIATED) OR (GENE (W) GUN) OR (NEED- LELESS (W) INJECTOR))
S8	20	S2 AND (CMV OR PRV)
S9	9	RD (unique items)
?s	s2 and (gold or tungsten)	
	407	S2
	75743	GOLD
	6523	TUNGSTEN
S10	0	S2 AND (GOLD OR TUNGSTEN)
?s	s2 and (microprojectile)	
	407	S2
	560	MICROPROJECTILE
S11	0	S2 AND (MICROPROJECTILE)
?s	s2 and (immunization or vaccination)	
	407	S2
	165852	IMMUNIZATION
	119028	VACCINATION
S12	1	S2 AND (IMMUNIZATION OR VACCINATION)
?t	s12/3,k/all	

12/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13058765 BIOSIS NO.: 200100265914

Characterization of a *minimal* *promoter* for human OX2.

AUTHOR: Chen Zhiqi(a); Marsden Philip(a); Gorczynski Reginald(a)

AUTHOR ADDRESS: (a)University Health Network, 200 Elizabeth Str, CCRW2-855,

Toronto, Ontario, M5G2C4**Canada
JOURNAL: FASEB Journal 15 (4):pA698 March 7, 2001
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies
for Experimental Biology on Experimental Biology 2001 Orlando, Florida,
USA March 31-April 04, 2001
ISSN: 0892-6638
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

Characterization of a *minimal* *promoter* for human OX2.

...ABSTRACT: a suppressive signal in alloactivated cell cultures, seems to be associated in vivo with prolongation of graft survival in animals receiving pre-transplant donor-specific *immunization*. We have cloned from a PAC library the human genomic OX2, detecting, in a 1500bp sequence, a previously uncharacterized region upstream of the first exon

...regulation of transcription in the region 5' to the transcriptional start site. We have cloned the full-length 1500 bp fragment into a pGL2 basic *vector* and used this to transfect a number of different mammalian cells, showing no, inducible or constitutive expression of OX2. Our data confirms that this sequence...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*minimal* *promoter*--
...METHODS & EQUIPMENT: analytical method, gene expression/*vector* techniques, genetic method

?ds

Set	Items	Description
S1	2770	(MINIMAL (W) PROMOTER) OR (ENHANCERLESS (W) PROMOTER) OR (- TRUNCATED (W) PROMOTER)
S2	407	S1 AND (VECTOR OR PLASMID)
S3	0	S2 AND ((DNA OR GENETIC) (W) (VACCINATION))
S4	1	S2 AND (IMMUNE (W) RESPONSE)
S5	17	S2 AND (ANTIGEN)
S6	0	S2 AND (COATED (W) PARTICLES)
S7	0	S2 AND ((PARTICLE (W) MEDIATED) OR (GENE (W) GUN) OR (NEEDLELESS (W) INJECTOR))
S8	20	S2 AND (CMV OR PRV)
S9	9	RD (unique items)
S10	0	S2 AND (GOLD OR TUNGSTEN)
S11	0	S2 AND (MICROPROJECTILE)
S12	1	S2 AND (IMMUNIZATION OR VACCINATION)

?logoff

03apr02 16:01:49 User259876 Session D331.2
\$2.69 0.841 DialUnits File155
\$2.31 11 Type(s) in Format 3
\$2.31 11 Types
\$5.00 Estimated cost File155
\$6.57 1.173 DialUnits File5
\$12.25 7 Type(s) in Format 3
\$12.25 7 Types
\$18.82 Estimated cost File5
\$8.52 0.947 DialUnits File73
\$25.00 10 Type(s) in Format 3
\$25.00 10 Types
\$33.52 Estimated cost File73
OneSearch, 3 files, 2.961 DialUnits FileOS
\$1.95 TELNET
\$59.29 Estimated cost this search
\$59.60 Estimated total session cost 3.041 DialUnits